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K e y  M e s s a g e s 
1. A comprehensive hepatitis B virus (HBV) 
array providing simultaneous analysis of HBV 
genotypes, mutations of reverse-transcriptase 
polymerase gene and mutations of S gene was 
developed.
2. The specificity and sensitivity of the HBV array 
was validated through analysis of 506 serum 
samples.
3. The array demonstrated improved sensitivity 
compared with existing commercial kits, with a 
detection limit down to ~28 copies/mL of HBV. 
Hepatitis B virus array for genotyping and 
mutation detection
Introduction
Hepatitis B virus (HBV) infection is a serious global 
health problem affecting about 2 billion people 
worldwide, of whom 350 million are chronic HBV 
carriers. The HBV is the tenth leading cause of death, 
with about one million deaths annually secondary 
to chronic hepatitis, cirrhosis, or hepatocellular 
carcinoma (HCC).1 The HBV is virtually endemic 
throughout Asia and Africa, and most chronic 
HBV infections are acquired perinatally or during 
childhood. For individuals with HBV infection, 
antiviral treatment is an effective way to reduce 
morbidity and mortality, and life-long antiviral 
therapy is advocated.2 However, in some patients, 
resistant viral strains carrying mutations in the B, 
C, and D domains of the HBV reverse transcriptase 
(rt) polymerase gene may emerge with prolonged 
therapy.3 These patients then have a higher risk of 
developing HCC than patients without resistant 
virus. Close monitoring of serum for early detection 
of any drug-resistant mutant is important to enable 
timely switching to or adding of other antiviral drugs 
to achieve adequate viral suppression.
 For patients who have undergone liver 
transplantation for hepatitis B–related end-stage 
liver disease, prophylaxis against recurrent HBV 
infection is given by administration of hepatitis 
B immunoglobulins derived from vaccinated 
subjects. The emergence of immune escape HBV 
mutants results in viral persistence despite adequate 
antibody titres. Identification of such S gene 
mutations helps devise alternative vaccines or post-
transplant prophylaxis.4 Different genotypes of HBV 
may predispose to disease complications (such as 
cirrhosis or HCC) and response to treatment.
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 Kits for the separate determination of viral 
mutants and genotypes are commercially available. 
The design of a comprehensive array to enable 
simultaneous detection of rt polymerase gene 
mutations, S gene mutations, and genotypes is 
useful.
Methods
This study was conducted from November 2006 to 
October 2008. Oligonucleotide primers pertaining 
to both the wild type and mutant sequences at the 
various positions along the rt polymerase and S genes 
of HBV were spotted onto coated glass slides. Each 
slide contained two sections of oligonucleotides for 
analysis of two different test samples. In addition, in 
each section, the oligonucleotides were spotted six 
times. Oligonucleotides for the detection of the eight 
genotypes of HBV were also spotted. Asymmetric 
polymerase chain reaction (PCR) product of the HBV 
gene fragment was prepared from a patient’s serum 
DNA and used in an allele-specific arrayed primer 
extension reaction (AS-APEX) on the spotted array 
as described previously.5
 Serum DNA from 100 unrelated HBV patients 
was analysed. The results were compared with those 
assayed previously using a commercial kit (Inno-
Lipa HBV Genotyping assay; Innogenetics, Ghent, 
Belgium). Samples with discordant results were 
sequenced to ascertain the correct mutation.
 Sensitivity and specificity of the array were 
confirmed by analysing serial samples from 45 HBV 
patients on long-term follow-up at the hepatology 
clinic of the Queen Mary Hospital. Typically 
serum samples were collected pre-treatment and 
five to seven times during therapy over a period of 
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It also enabled early detection of emergence of 
drug-resistant mutants.
4. The array may be useful for clinicians in making 
timely decisions on switching to alternative 
drugs.
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1 to 3 years. The results of the array analysis were 
compared with those detected with the Inno-Lipa 
kit. Genotypes of these samples were also recorded.
 Quantitative PCR based on the TaqMan 
Technology was used to assess the copy number of 
HBV mutants in five different HBV serum samples. 
Each serum sample was then subjected to a serial 
doubling dilution with the same starting copy 
number of Eurohep (HBV standard DNA sequence 
containing the wild-type virus only). These diluted 
samples were then used for array analysis. The 
minimum amount (copy number/mL) of mutant 
strain detectable was calculated. The experiment 
was repeated twice for each of the five samples.
 In addition to analysis of samples from Chinese 
patients with hepatitis B, 25 samples from patients 
of other ethnicities were analysed to validate the 
eight oligonucleotides for the determination of 
HBV genotypes. These samples were also assayed 
by the commercial kit (Inno-Lipa HBV Genotyping 
assay) and sequencing was performed to confirm the 
genotypes.
Results
Of the initial 100 HBV patients’ samples analysed, 
56 samples gave concordant results with mutations 
detected by the array as well as the Inno-Lipa 
HBV Genotyping assay. In 43 samples, additional 
mutations were detected on the array. The presence 
of these mutations was confirmed by sequencing.
 Results of samples from most patients were 
concordant using both the array and the Inno-Lipa 
kit. In a few patients, the emergence of drug-resistant 
mutations was detected 3-7 months prior to overt 
biochemical relapse of hepatitis. This indicates the 
enhanced sensitivity of the array. In addition, it was 
possible to assay by array samples containing <60 
c/mL of HBV (as the lower limit determined by the 
commercial quantitative PCR kit). The Table shows 
the results of four selected patients on longitudinal 
follow-up.
 Serial dilutions of one serum sample with an 
equal amount (viral copy number) of Eurohep, PCR 
amplification, and analysis by the array showed 
that it was possible to detect the mutants down to 
a minimum of 139 c/mL at a dilution of 1:20 480. 
By diluting the first PCR product an extra 10-fold 
from a 1:10 240 dilution (ie final dilution of 1:102 
400), it was possible to achieve a detection limit of 28 
c/mL. Similar results were obtained for the other 
four serum samples tested.
 Oligonucleotides for the detection of HBV 
genotypes were validated from 25 serum samples 
sent from our overseas collaborator. It was possible 
to validate oligonucleotides for genotypes A, B, C, D, 
* Earlier detection of mutants by hepatitis B virus array
TABLE.  Longitudinal follow-up study of patients receiving antiviral therapy
Patient no: drug (date taken) Serum sample (date taken)
Follow-up
Initial I II III IV V VI VII
Patient 1: lamivudine (97), LG (04) AA67 (11/8/97) (A67) AA68 (20/5/04)* AA69 (9/6/04) AA70 (14/6/04) AA71 (30/6/04) AA72 (20/10/04) AA73 (6/4/05) AA74 (28/7/05)
Results using commercial kit 424.5 x106 c/mL ( lamivudine↓, 
LG ↓)
3.74 x106 c/mL (180M, 204V) 3.44 x105 c/mL (80I, 80V, 
180M, 204I)
6 x104 c/mL (80I, 80V, 180M, 
204I)
4.17 x104 c/mL (Adefovir↓ 
at 26/9/04) (80I, 80V, 180M, 
204I)
1.37 x104 c/mL (80V, 80I, 
180M, 204I)
45 x106 c/mL (80V, 80I, 
180M, 204I)
113 x106 c/mL (80V, 80I, 
180M, 204I) [5/06 stopped 
adefovir]
Results of both genotype, and mutants 
detected by the array
C: wild type only C: L80, 80I, 80V, V84, 84M, 
L180, 180M, 204I
C: L80, 80I, 80V, V84, 84M, 
L180, 180M, 204I
C: L80, 80I, 80V, V84, 84M, 
L180, 180M, 204I
C: L80, 80I, 80V, 180M, 204I C: 80I, L180, 180M, 240I C: 80I, L180, 180M, 204I C: L80, 80I, 80V, L180, 
180M, 204I
Patient 2: lamivudine, LG AA83 (3/9/97) AA84 (8/9/04)* AA86 (12/10/04) AA85 (19/10/04) AA87 (23/11/04) AA88 (21/12/04)
Results using commercial kit 311.3 x106 c/mL (Lamivudine↓  
LG↓)
28.1 x106 c/mL (180M, 204I) 1.63 x106 c/mL (80I, 80V, 
180M, 204I)
3.45 x105 c/mL (80I, 80V, 
180M, 204I)
7.24 x103 c/mL (80I, 80V, 
180M, 204I)
345 c/mL (adefovir↓)
Results of both genotype, and mutants 
detected by the array
C: wild type only C: 80I, 80V, L82, 82M, L180, 
180M, 204I
C: 80I, 80V, L180, 180M, 
204I
C: 80I, 80V, L82, 82M, L180, 
180M, 204I
C: 80I, 80V, L180, 180M, 
?180V, 204I
C: L80, 80I (wk), T126, 
126A (S gene)
Patient 3: adefovir (15/11/03) 50 (13/1/04)* M1 (14/6/04) M2 (21/9/04) M4 (14/12/04) M3 (30/3/06) M5 (24/7/06)
Results using commercial kit 8.26 x105 c/mL (80I, 180M) 1.2 x103 c/mL (80I, 180M, 
L180, 204I)
1.65 x102 c/mL No polymerase chain 
reaction product
1.0 x104 c/mL (80I, 180M) 0.91 x102 c/mL
Results of both genotype, and mutants 
detected by the array
B, C: S78, T78; 80I, S85, 85A, 
L179, 179P, 180M, V191, 191I, 204I
B: 80I, 180M, 204I B: L82, 82M, T128, 128A, 
V207, 207M
B: L80, 80I, T128, 128A, 
L180, 180M, M204, 204I
B: 80I, T128, 128A, 180M, 
204I
Patient 4 37 (26/4/04) N1 (3/1/05)* N2 (5/12/05) N4 (14/3/06) N5 (12/6/06) N3 (29/9/06)
Results using commercial kit 7.9 x104 c/mL (80V, 80I) <2000 c/mL (no polymerase 
chain reaction product) 
[10/10/05 11935 c/mL 80I]
1.6 x103 c/mL 3.79 x103 c/mL (80I weak) 1.85 x103 c/mL 549 c/mL
Results of both genotype, and mutants 
detected by the array
C: L80, 80I, 128A, L180, 180M, 
229V (S gene)
C: 80I, 128A, 204I C: 80I, 128A, 204I C: 80I, 128A, 204I C: 80I, 128A, 204I, T131, 
131I (S gene)
C: L80, 80I, 128A, 204I, 
T131, 131I (S gene)
